471 related articles for article (PubMed ID: 18487222)
21. BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists.
Wang S; Zhang B; Faller DV
EMBO J; 2004 Jun; 23(11):2293-303. PubMed ID: 15141164
[TBL] [Abstract][Full Text] [Related]
22. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.
Nickols NG; Dervan PB
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10418-23. PubMed ID: 17566103
[TBL] [Abstract][Full Text] [Related]
23. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
Makkonen H; Kauhanen M; Paakinaho V; Jääskeläinen T; Palvimo JJ
Nucleic Acids Res; 2009 Jul; 37(12):4135-48. PubMed ID: 19433513
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
25. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
26. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
27. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
28. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Masiello D; Cheng S; Bubley GJ; Lu ML; Balk SP
J Biol Chem; 2002 Jul; 277(29):26321-6. PubMed ID: 12015321
[TBL] [Abstract][Full Text] [Related]
29. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
30. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.
Rosenblatt AE; Burnstein KL
Mol Endocrinol; 2009 Mar; 23(3):412-21. PubMed ID: 19131511
[TBL] [Abstract][Full Text] [Related]
32. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
33. Ligand-specific dynamics of the androgen receptor at its response element in living cells.
Klokk TI; Kurys P; Elbi C; Nagaich AK; Hendarwanto A; Slagsvold T; Chang CY; Hager GL; Saatcioglu F
Mol Cell Biol; 2007 Mar; 27(5):1823-43. PubMed ID: 17189428
[TBL] [Abstract][Full Text] [Related]
34. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
35. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
[TBL] [Abstract][Full Text] [Related]
36. 2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.
Shah S; Hess-Wilson JK; Webb S; Daly H; Godoy-Tundidor S; Kim J; Boldison J; Daaka Y; Knudsen KE
Mol Cancer Res; 2008 Sep; 6(9):1507-20. PubMed ID: 18819937
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
38. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor interacts with telomeric proteins in prostate cancer cells.
Kim SH; Richardson M; Chinnakannu K; Bai VU; Menon M; Barrack ER; Reddy GP
J Biol Chem; 2010 Apr; 285(14):10472-6. PubMed ID: 20110352
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
